Hims Hers Health Inc (HIMS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Hims Hers Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 30.80 $ — 33% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
6/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 89.6%
- Exp. sales growth 3Y > 5% 33.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 11.4%
- Net debt < 4x EBIT 5.1x
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% 193.1%
- ROCE > 15% 6.0%
- Expected return > 10% 12.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 64.5% passed
- More than 10% revenue growth is expected for the coming year 41.6% passed
- Share count grows by less than 3% a year 8.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 62.2% passed
- Gross margin at 40% or higher and without meaningful erosion 73.8% failed
- Goodwill from acquisitions does not grow faster than revenue 12.9% passed
- Net debt below twice EBITDA 3.0 x EBITDA failed
- Operating cash flow covers the profits of the last three years 394 m passed
- Return on capital at 15% or higher, or up versus two years ago 6.0% passed
- Insiders hold at least 10% or are net buyers 5.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 5.1% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.13 | -0.18 – -0.08 | 3,048 | -38.1% | 2 |
| 12/31/2027 | 0.62 | 0.42 – 0.97 | 4,158 | 91.3% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.07 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.11 | 1,721.30 | 481 | 95.10 | 5.40 | 86 | 60 |
| 2025: Q1 | 0.20 | 313.60 | 586 | 110.70 | 8.40 | 109 | 50 |
| 2025: Q2 | 0.17 | 192.30 | 545 | 72.60 | 7.80 | -19 | -69 |
| 2025: Q3 | 0.06 | -80.30 | 599 | 49.20 | 2.60 | 149 | 91 |
| 2025: Q4 | 0.08 | -23.20 | 618 | 28.40 | 3.30 | 65 | 1 |
| 2026: Q1 | -0.40 | -301.00 | 608 | 3.80 | -15.10 | 89 | 53 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 27 | -76 | -75 | -1.12 | -57 | 23 | 48 |
| 2019 | 83 | -74 | -72 | -2.07 | -75 | -135 | 72 |
| 2020 | 149 | -15 | -18 | -0.51 | -2 | -147 | 119 |
| 2021 | 272 | -115 | -108 | -0.58 | -34 | 335 | 421 |
| 2022 | 527 | -69 | -66 | -0.32 | -27 | 312 | 366 |
| 2023 | 872 | -29 | -24 | -0.11 | 73 | 344 | 441 |
| 2024 | 1,477 | 62 | 126 | 0.53 | 251 | 477 | 708 |
| 2025 | 2,348 | 106 | 128 | 0.50 | 300 | 541 | 2,155 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Hims & Hers Health, Inc. betreibt eine verbraucherorientierte Gesundheits- und Wellnessplattform, die Verbraucher mit lizenzierten Gesundheitsfachkräften in den USA, dem Vereinigten Königreich, Kanada, Deutschland, Irland, Frankreich, Spanien und international verbindet.
| Employees | 2,442 |
|---|---|
| Headquarters | San Francisco, CA |
| Address | 2269 Chestnut Street, 94123 San Francisco, United States |
| Phone | 415 851 0195 |
| Website | hims.com |
| IPO Date | 13. Sep 2019 |
| ISIN | US4330001060 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Andrew Dudum | Co-Founder, Chairman & CEO | 1988 |
| Oluyemi Okupe | Chief Financial Officer | 1986 |
| Mike Chi | Chief Operating Officer | 1980 |
| Mohamed ElShenawy | Chief Technology Officer | 1975 |
| Soleil Teubner Boughton J.D. | Chief Legal Officer & Corporate Secretary | 1978 |
| Patrick Carroll M.D. | Global Chief Medical Officer | 1958 |
| Deborah M. Autor J.D. | Chief Policy Officer & Director | 1967 |
| Irene A. Becklund | Chief Accounting Officer | 1984 |
| William James Newby | Senior Director of Investor Relations | – |
| Kathryn H. Beiser B.A., M.S. | Chief Communications Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 17. Jul 2026 | Okupe Oluyemi | Chief Financial Officer | Sell | 7,163 | 31.99 | 229,168 |
| 17. Jul 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 7,163 | 5.01 | 35,887 |
| 20. Apr 2026 | Oluyemi Okupe | CFO | Sell | 19,645 | 29.96 | 588,564 |
| 20. Apr 2026 | Soleil Boughton | Insider | Sell | 9,463 | 30.00 | 283,890 |
| 17. Apr 2026 | Oluyemi Okupe | CFO | Sell | 18,005 | 27.83 | 501,079 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.